扶正固本汤对恶性肿瘤化疗后临床疗效观察

目的:观察扶正固本汤对恶性肿瘤化疗后临床疗效影响。方法:将所有于我院肿瘤科住院的恶性肿瘤患者共80例,随机分为治疗组与对照组两组,每组各40例。所有患者均按西医常规术后处理原则及化疗后处理原则给予相应的治疗措施。治疗组根据肿瘤的部位及类型选择不同的手术方式及化疗方案。两组所有手术患者均于术后10¹4 d开始化疗,至少用药2个周期以上,在对照组相同治疗的基础上,在开始化疗的第1天即加用中药扶正固本汤口服。疗程3个月。两组均疗程结束后观察疗效。结果:治疗结束后统计显示,在两组客观有效率比较中,治疗组为75.00%,对照组为65.00%,两组相比,有统计学差异(P<0.05)。在两组治疗前后Karnofsky评分比较中,治疗组好转率为57.5%,对照组好转率为32.5%,两组相比,有统计学差异(P<0.05)。在两组治疗前后体重增长情况比较中,治疗组好转率为47.5%,对照组好转率为30.0%,两组相比,有统计学差异(P<0.05)。在两组治疗前后白细胞计数与T细胞亚群比较中,治疗组在治疗后白细胞计数、CD4细胞CD8细胞NK细胞计数均明显高于对照组,两组相比,差异显著(P<0.05)。在两组治疗前后心肌射血分数(LVEF)及心肌钙蛋白水平比较中,治疗组在治疗后,心肌射血分数为(0.54±0.05),对照组为(0.42±0.04),治疗组明显高于对照组,差异有统计学意义(P<0.05),治疗组在治疗后,肌钙蛋白水平(0.44±0.05),对照组为(0.55±0.08),治疗组明显低于对照组,差异有统计学意义(P<0.05),两组治疗后化疗毒副反应比较,治疗组在骨髓抑制、恶心呕吐、腹泻、乏力、肝功能损害等方面均低于对照组,有统计学差异(P<0.05)。结论:口服中药扶正固本汤可以提高患者的临床缓解率,能明显提高患者的Karnofsky评分及体重,有效地改善患者的生活质量,此外还可以提高患者白细胞及免疫T细胞亚群数量,调节免疫功能,还能有效地减少化疗药物对心脏引起的损害,在很大程度上减少了化疗药物的毒副反应,值得临床推广使用。

Clinical Efficacy of Fuzheng Guben Decoction after Chemotherapy of Malignant Tumor

Objective： To observe the clinicalcurative effect of Fuzheng Guben Decoction on malignant tumor patients after chemotherapy. Methods： 80 patients with malignant tumor in tumor department of our hospitalwererandomly divided into treatment group and control group,40 patients in each group. The treatment group according to thelocations and types oftumor used different ways of operation and chemotherapy. Two groups both began chemotherapy 10- 14 days after operation,at least 2 cycles. Based on the sametreatment,the treatment group at the start of the first day of chemotherapy used Fuzheng Guben Decoction. The course of treatment was 3 months. Clinical observation at the end of the two groups after treatment was carried out. Results： After the treatment,the efficiency was 75% in treatment group and that of the control group was 65% and there was statistically significant difference（ P〈0. 05）. In the comparison of Karnofsky score before and after treatment in two groups,the treatment group＇s cure rate was 57. 5% and control group＇s improvement rate was32. 5% and there was statistically significant difference（ P〈0. 05）. The treatment group＇s improved weightrate was47. 5% and that of the control groupwas 30% and there was statistically significant difference（ P〈0. 05）. Thewhite blood cell count and T cell subsets,CD4 cell CD8 cell NK cell counts in the treatment group were significantly higher than those in control group（ P〈0. 05）. After the treatment,the cardiacejection fraction（ LVEF）（ 0. 54 ± 0. 05） in treatment groupwas significantly higher than that（ 0. 42 ± 0. 04） of the control group and the difference was statistically significant（ P〈0. 05）. The treatment group＇s cardiac troponin level（ 0. 44 ± 0. 05） was significantly lower than（ 0. 55 ± 0. 08）of the control group and the difference was statistically significant（ P〈0. 05）. The treatment group＇s bone marrow suppression,nausea and vomiting,diarrhea,fatigue,liver function damage were lower